Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01234558 · ClinicalTrials.gov registry record · Phase 2
Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression
A Phase 2 study, sponsored by Naurex, Inc, an affiliate of Allergan.
- Completed
- Registry status
- Phase 2
- Development phase
- 115
- Enrollment target
NCT01234558: Completed Phase 2 study, sponsored by Naurex, Inc, an affiliate of Allergan.
NCT01234558 is a Phase 2 study that has completed, run by Naurex, Inc, an affiliate of Allergan. The registered enrollment target is 115 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01234558, a Phase 2 study, has completed, sponsored by Naurex, Inc, an affiliate of Allergan.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 115 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
Interventions
- DRUG GLYX-13
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 115 participants |
| Start Date | 2011-05 |
| Est. Completion | 2012-07 |
| Phase | Phase 2 |
What the finished NCT01234558 record still lists
NCT01234558 is an interventional study that assigns participants to a tested intervention. The registered 115 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (14% lower).
The record links to 0 conditions, and to 1 intervention - of which GLYX-13 is the first listed.
NCT01234558 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01234558 about?
NCT01234558 is a clinical study titled "Single IV Dose of GLYX-13 in Patients With Treatment-Resistant Depression". The purpose of this study is to determine whether GLYX-13 reduces depression score in patients with treatment-resistant depression.
What is the current status of trial NCT01234558?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 115 participants. The study started on 2011-05. Estimated completion is 2012-07.
What interventions are being tested in trial NCT01234558?
The interventions under investigation include: GLYX-13 (DRUG).
Who is sponsoring clinical trial NCT01234558?
This trial is sponsored by Naurex, Inc, an affiliate of Allergan, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01234558's enrollment target sits among peer trials
115 626th of 2000 higher than 1,374 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02346929 · 115 participants · NA
Hematoma Block for Distal Radius Fracture
- NCT03394365 · 115 participants · Phase 3
A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy
- NCT03907475 · 115 participants · Phase 2
Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial
- NCT05086692 · 115 participants · Phase 1
A Beta-only IL-2 ImmunoTherapY Study
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia